CXCR4 and androgen insensitivity syndrome: These findings suggest that targeting TGF‐β1 signaling may offer promising therapeutic strategies for LAA strokes, while CXCR4 inhibition could benefit CE strokes, providing etiology‐specific approaches to improve AIS outcomes.